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Abstract
The efficacy of pharmacotherapy for PTSD, anxiety, and depression among combat veter-
ans is not well-established.
Objectives
To estimate the effect of pharmacotherapy on PTSD, anxiety, and depression among com-
bat veterans; to determine whether the effects varied according to patient and intervention
characteristics; and to examine differential effects of pharmacotherapy on outcomes.
Materials and Methods
Google Scholar, PILOTS, PsycINFO, PubMed, and Web of Science databases were
searched through November 2014. Searches resulted in eighteen double-blind, placebo
controlled trials of 773 combat veterans diagnosed with PTSD and included only validated
pre- and post-intervention PTSD and anxiety or depression measures. Authors extracted
data on effect sizes, moderators, and study quality. Hedges’ d effect sizes were computed
and random effects models estimated sampling error and population variance. The John-
son-Neyman procedure identified the critical points in significant interactions to define re-
gions of significance.
Results
Pharmacotherapy significantly reduced (Δ, 95%CI) PTSD (0.38, 0.23-0.52), anxiety (0.42,
0.30-0.54), and depressive symptoms (0.52, 0.35-0.70). The effects of SSRIs and tricyclic
antidepressants on PTSD were greater than other medications independent of treatment
duration. The effect of SSRIs and tricyclic antidepressants were greater than other medica-
tions up to 5.2 and 13.6 weeks for anxiety and depression, respectively. The magnitude of
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the effect of pharmacotherapy on concurrently-measured PTSD, anxiety, and depression
did not significantly differ.
Conclusions
Pharmacotherapy reduced PTSD, anxiety, and depressive symptoms in combat veterans.
The effects of SSRIs and tricyclic antidepressants were greater for PTSD and occurred
quicker for anxiety and depression than other medications.
Introduction
Posttraumatic stress disorder (PTSD) is a debilitating trauma-related disorder resulting from
exposure to a traumatic event or events [1]. PTSD is a pervasive problem among military per-
sonnel who have experienced combat [2]. The lifetime prevalence of combat-related PTSD in
US combat veterans ranges from approximately 6% to 31% [3]. With over 21.2 million military
veterans in the US population, approximately 1.3 to 6.6 million veterans will experience PTSD
during their lifetime [4].
Since September 11, 2001, over 2.4 million American service members have served in Iraq
or Afghanistan with over 1 million service members deployed twice or more to war zones [5].
Consequently, the Veterans Health Administration and military healthcare systems have seen
dramatic increases in cases of combat-related PTSD and depressive and anxiety disorders.
Over 54% of the approximately 934,000 OEF/OIF/OND veterans utilizing Veterans Health Ad-
ministration facilities since 2001 have received diagnosis for a mental health disorder. PTSD
(29.4%), depressive disorders (23.2%), and anxiety disorders (20.7%) were the most frequent
diagnoses [6].
The 2010 National Defense Authorization Act requested that the Institute of Medicine
(IOM) examine the effectiveness of the growing number of PTSD programs and services avail-
able to service members and veterans in DoD and VA, respectively. The IOM committee’s re-
port [7] indicated that, although there is a wealth of information on PTSD, there are also
substantial gaps in our knowledge of how best to manage PTSD in service members and veter-
ans diagnosed with PTSD [7].
Pharmacotherapy is a common method of treating combat-related PTSD [8]. Several phar-
macological approaches have been investigated in the treatment of PTSD (e.g., antidepressants,
adrenoreceptor antagonists, anticonvulsants, atypical antipsychotics, benzodiazepines), but the
efficacy of pharmacotherapy for PTSD has not been well-established [9]. The aforementioned
IOM committee report specifically identified several gaps in PTSD-treatment research in com-
bat-veterans relative to pharmacotherapy to include: (i) further examination of pharmacother-
apy for PTSD comorbid with other disorders, and, (ii) concern that although polypharmacy
may result in improvement in PTSD symptoms, it may also result in more side effects and con-
tribute to noncompliance to treatment [7]. These issues may be related to the high comorbidity
of PTSD with symptoms of other psychological disorders like depression and anxiety or the
treatment of specific symptoms (e.g., insomnia, flashbacks) rather than diagnosed psychologi-
cal disorders [8]. Thus, there is a need to identify which drug classes best manage PTSD symp-
toms in conjunction with other comorbid psychological symptoms among veterans. These
issues are both examined in the current review.
Selective serotonin re-uptake inhibitors (SSRIs) have shown efficacy as a first-line pharmaco-
therapy, but less than 60% of patients respond to treatment [10]. Other pharmacotherapies have
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shown similar efficacy to SSRIs, but are less well tolerated and therefore have not become first
line therapies [9]. Although the efficacy of different classes of drugs remains uncertain, treating
co-occurring disorders and symptoms, such as depression and anxiety, is essential in maximiz-
ing treatment outcomes in combat-related PTSD [8]. For example, the National Vietnam Veter-
ans Readjustment Study indicated that 98.9% of veterans with PTSDmet criteria for a lifetime
comorbid psychiatric diagnosis [11]. The high comorbidity of anxiety and depressive symptoms
likely exacerbates the chronic, debilitating effects of PTSD and the resistance to treatment. Thus,
there also is a need to identify whether different pharmacological approaches differentially affect
PTSD and other comorbid psychological conditions like anxiety and depression.
Although the majority of empirical research has focused on SSRIs, prior reviews have sup-
ported the efficacy of numerous short- and long-term pharmacotherapies for PTSD [12, 13],
including PTSD diagnoses with comorbid anxiety and depressive symptoms [14]. A prior sys-
tematic review which focused on combat-related PTSD supported the efficacy of pharmaco-
therapy for PTSD among combat veterans [14], but did not focus on the best available
evidence (e.g., randomized controlled trials (RCTs) of pharmacotherapy) and was limited by
the use of inadequate statistical models. Moreover, no systematic review has examined the po-
tential differential effects of pharmacotherapy across concurrently-measured PTSD, anxiety,
and depressive symptoms among combat veterans with PTSD.
Thus, the primary aims of this systematic review were: (1) to estimate the effect size for phar-
macotherapy on combat-related PTSD, anxiety, and depressive symptom severity among com-
bat veterans; (2) to determine whether the effects varied according to patient characteristics and
modifiable features of pharmacotherapy; and, (3) to examine potential differential effects of
pharmacotherapy on concurrently-measured PTSD, anxiety, and depressive symptoms.
Materials and Methods
This systematic review and meta-analysis was conducted in accordance with the Preferred Re-
porting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines [15].
As detailed in the authors’ previously published systematic reviews, standard methods were
used for data extraction and quality assessment [16–19], data synthesis and analysis [16–19],
meta-regression analysis [16–19], and differential effects analysis [18].
Data Sources and Searches
Electronic searches of databases were conducted via Google Scholar, PILOTS, PsycINFO,
PubMed, and Web of Science from database inception to November 2014 using the search
strategy: (Posttraumatic Stress Disorder or PTSD) and (pharmacotherapy or pharmacological
treatment) and (combat or combat veteran or military or military personnel or war or war vet-
eran or veteran) and (anxiety or depression). Searches were restricted to randomized controlled
trials. Reference lists from retrieved articles were manually searched.
Study Selection
Inclusion criteria were: (1) a sample that included only combat veterans diagnosed with PTSD,
(2) randomized, double-blind allocation to either pharmacotherapy or placebo condition, and
(3) a PTSD symptom severity outcome measured at baseline and during and/or post-interven-
tion. Exclusion criteria were: (1) use of nonrandomized, uncontrolled, or open trial designs; (2)
failure to include or specify the inclusion of combat veterans with PTSD; (3) lack of data neces-
sary for the calculation of effect size for PTSD; or (4) failure to use a validated PTSD outcome
measure [20]. Fig 1 presents a flowchart of study selection.
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Data Extraction and Quality Assessment
Data were independently extracted by the authors and discrepancies were resolved by consen-
sus judgment. Effect sizes were calculated by subtracting the mean change in the comparison
condition from the mean change in the treatment condition and dividing the difference by the
pooled standard deviation of baseline scores [21]. Effect sizes were adjusted for small sample
size bias and calculated so that decreases in PTSD, anxiety, and depression resulted in positive
Fig 1. Flow Chart of Study Selection.
doi:10.1371/journal.pone.0126529.g001
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effect sizes [21]. When a standard deviation was not reported (k = 1) [22] it was estimated [23]
from the largest study of combat-related PTSD using the same PTSD symptom severity mea-
sure [24]. Two-way (Effects x Raters) intraclass correlation coefficients (ICC) for absolute
agreement were calculated to examine inter-rater reliability for symptom effect sizes and mod-
erators. The initial ICCs, based on 10 effects, were0.90.
Authors independently assessed study quality using a widely recognized method that ad-
dressed randomization, sample selection, quality of outcome measures, and statistical analysis
[25]. Quality scores were reported for each study for descriptive purposes, but were not used as
weights or moderators in the analysis because of the potential disparity in results that depends
on the specific quality scale employed [26].
Data Synthesis and Analysis
Separate statistical analyses were performed for effects of pharmacotherapy on PTSD, anxiety,
and depressive symptom severity. Meta-regression was used as the primary analysis of modera-
tor effects in each of these models in order to reduce the probability of type I error by comput-
ing simultaneous estimates of independent effects by multiple moderator variables on the
variation in effect size across trials.
An SPSS macro (i.e.,MeanES; SPSS version 22.0, SPSS Inc., Chicago, IL) was used to calcu-
late the aggregated mean effect size delta (Δ), associated 95% confidence interval, and the sam-
pling error variance according to a random effects model [27]. Random effects models were
used to account for between-studies heterogeneity associated with both study-level sampling
error and population variance [27]. Each effect was weighted by the inverse of its variance and
re-estimated after the random effects variance component was added [21]. Heterogeneity and
consistency were evaluated with the Q statistic and the I2 statistic, respectively [28]. Heteroge-
neity also was examined relative to observed variance and was indicated if the sampling error
accounted for less than 75% of the observed variance [21]. Publication bias (i.e., smaller studies
showing larger effects) was addressed by inspection of a funnel plot [29] and quantified with
rank correlation and regression methods [29, 30].
Primary Moderators
Three primary moderators were selected based on logical, theoretical, or empirical relations
to PTSD, anxiety, depression, and/or pharmacotherapy: type of pharmacotherapy, treatment
duration, and pharmacotherapy x duration interaction. These variables were tested in each
model that met criteria for heterogeneity of effects. Definitions of these variables can be
found in S1 Table.
Primary Moderator Analysis
An SPSS macro (MetaReg; SPSS version 22.0, SPSS Inc., Chicago, IL) was used to conduct sepa-
rate moderator analyses for PTSD, anxiety, and depression symptom severity models [27]. For
each model, primary moderator variables were included in a random-effects multiple linear re-
gression analysis with maximum-likelihood estimation [21, 27] adjusted both for non-inde-
pendence of multiple effects contributed by single studies [31] and for age because of its
univariate association with outcomes. Tests of the regression model (QR) and its residual error
(QE) are reported for each model. Significant categorical moderators in the regression analyses
were decomposed using a random effects model to compute mean effect sizes and 95% confi-
dence intervals [27]. The Johnson-Neyman procedure was conducted to identify the critical
point in significant interactions of categorical and continuous variables in order to define re-
gions of significance [32, 33].
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Secondary Moderators and Analysis
Secondary moderators were selected for descriptive, univariate analyses for PTSD, anxiety, and
depressive symptom severity models. These variables were grouped into patient characteristics
(i.e., age, sex, combat sample, baseline symptom score), intervention characteristics (i.e., phar-
macotherapy type, program duration, concomitant medication), and study design characteris-
tics (i.e., adherence, time period, outcome measure). Definitions for these variables can be
found in S1 Table. Random effects models were used to calculate mean effect sizes (Δ) and 95%
confidence intervals for continuous and categorical variables [27].
Direct Comparison of Concurrent Effects on PTSD, Anxiety, and
Depression
Pharmacotherapy investigations that concurrently measured PTSD, anxiety, and depressive
symptom severity were used to directly compare the magnitude of the effects among the three
mental health outcomes in combat veterans with PTSD. PTSD, anxiety, and depression effect
sizes were then dummy coded. Using a SPSS macro (MetaF; SPSS version 22.0, SPSS Inc., Chi-
cago, IL), mean effect sizes (Δ) and 95% confidence intervals were computed and the significance
of coded effect size variables was tested [27]. Differences among the effects for PTSD, anxiety,
and depressive symptoms were determined using theQB statistic [21]. For significant tests, pair-
wise contrasts were tested at p<0.05. Random effects models were used for all analyses [27].
Results
Eighteen trials of 773 combat veterans were included in the meta-analysis and are presented in
S1 References. Characteristics of included trials and study quality assessment are present in
Table 1. An annotated table of descriptors of the unweighted Hedge’s d effects is presented in
Table 2. Funnel plots for all analysis models were inspected and found to be roughly symmetri-
cal (S1, S2, and S3 Figs). The Begg’s rank correlation and Egger’s regression analyses were not
statistically significant for any of the models suggesting absence of publication bias (S2 Table).
PTSD Symptom Severity
PTSD symptom severity was significantly reduced after pharmacotherapy interventions (Δ =
0.38 (0.23 to 0.52); z = 5.24, p<0.001). The distribution of the effects is presented in Fig 2. The
effect was heterogeneous (QT(49) = 144.23, p<0.001). Sampling error accounted for 38.2% of
the observed variance. The effect was not consistent across studies (I2 = 66.7%; 95% CI, 61.4%
to 71.3%).
Moderator analysis
The overall multiple regression model for PTSD was significantly related to effect size (QR(5) =
58.14; p< 0.001, R2 = 0.50; QE(44) = 59.01, P = 0.065). Only type of pharmacotherapy (β =
0.77, z = 3.15, P = 0.002) was independently related to effect size. Significantly larger effects
were found in SSRIs and Tricyclic anti-depressants (Δ = 0.63, [95% CI, 0.48, 0.78]) compared
to the average of effect of all other drug therapies (Δ = 0.10, [95% CI, -0.05, 0.25]; QB(1) =
23.37, p<0.001).
Anxiety Symptom Severity
Anxiety was significantly reduced after pharmacotherapy interventions (Δ = 0.42 (0.30 to
0.54); z = 6.75, p<0.001). A distribution of effects is presented in Fig 3. The effect was
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heterogeneous (QT(27) = 44.01, p = 0.0206). Sampling error accounted for 62.7% of the ob-
served variance. The effect was moderately consistent across studies (I2 = 40.9, 95% CI, 25.6%
to 53.1%).
Moderator analysis. The overall multiple regression model for anxiety was significantly
related to effect size (QR(5) = 36.99; p< 0.001, R
2 = 0.84; QE(22) = 7.02, P = 0.999). The phar-
macotherapy x duration interaction (β = 0.06, z = 1.94, P = 0.050) was independently related to
effect size. The Johnson-Neyman procedure yielded critical points for treatment duration at
5.2 (t = -2.07, p = 0.050) and 11.0 weeks (t = 2.07, p = 0.050) when comparing the effects of
pharmacotherapy treatment using SSRIs and Tricyclic antidepressants and other drug classes.
Depressive Symptom Severity
Depression was significantly reduced after pharmacotherapy interventions (Δ = 0.52 (0.35 to
0.70); z = 5.81, p< 0.001). A distribution of effects is presented in Fig 4. The effect was hetero-
geneous (QT(38) = 159.58, p<0.001). Sampling error accounted for 42.6% of the observed vari-
ance. The effect was not consistent across studies (I2 = 76.8%; 95% CI, 73.0% to 80.1%).
Table 1. Characteristics of Included Trials.
PTSD Anxiety Depression
Study Characteristics:
Studies (n) 18 6 10
Effects (k) 50 28 40
Total Sample (N) 773 365 550
Patient Characteristics:
Age (mean, [SD]) 47.3 (7.8) 47.7 (8.7) 47.1 (8.8)
Male (%) 98.3 98.6 98.2
Time Since PTSD Diagnosis (years [SD]) 19.0 (9.9) 16.4 (9.2) 19.7 (9.8)
Number of Studies Reporting Time Since PTSD Diagnosis (n [%]) 5 (27.8) 2 (33.3) 3 (30.0)
Baseline Score (T-Score [SD]) 61.5 (11.1) 63.8 (7.4) 72.1 (11.8)
Intervention Characteristics:
Type of Medication (%)
Anticonvulsant 22.0 35.7 25.0
Antipsychotic 6.0 3.6 2.5
Novel Class 2.0 0.0 0.0
SSRI 24.0 28.6 20.0
Tricyclic 28.0 25.0 35.0
Other 18.0 7.1 17.5
Treatment Duration (weeks [SD]) 9.8 (5.3) 10.0 (6.6) 9.8 (5.9)
Treatment Adherence (% [SD]) 80.1 (13.9) 83.5 (10.5) 78.6 (13.9)
Number of Studies Reporting Treatment Adherence (n [%]) 12 (66.7) 5 (83.3) 8 (80.0)
Most Frequently Used Outcome Measures (k [%]) CAPS: 16 (32.0) HAM-A: 26 (92.9) MADRS: 18 (42.5)
CGI-S: 9 (18.0) BAI: 2 (7.1) HAM-D: 17 (45.0)
Study Quality:
Study Quality (mean rating [SD]) 11.6 (0.9) 12.4 (0.9) 12.1 (0.9)
Abbreviations: SSRI, Selective Serotonin Reuptake Inhibitor; CAPS, Clinician Administered PTSD Scale; CGI-S, Clinical Global Impression-Severity;
HAM-A, Hamilton Anxiety Rating Scale; BAI, Beck Anxiety Inventory; MADRS, Montgomery–Åsberg Depression Rating Scale; HAM-D, Hamilton
Depression Rating Scale.
doi:10.1371/journal.pone.0126529.t001
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Table 2. Annotated Descriptors of Unweighted Hedges’ d Effect Sizes.
Source Total
N
Age
(years)
Sample Drug Class Drug Name Duration
(weeks)
Adherence
(%)
PTSD
Scale
Hedges’ d
(95%CI)
Bartzokis et al.,
2004
48 51.6 US Vietnam
Veterans
Antipsychotic Risperidone 16 NR CAPS 0.67 (0.09 to
1.26)
Batki et al., 2014 30 50 US Mixed Conflict
Veterans
Anticonvulsant Topiramate 12 90 PCL-M 0.49 (-0.24 to
1.21)
Davidson et al.,
1990
40 53.6 US Mixed Conflict
Veterans
TCA Amitriptyline 8 71 CGI-S 0.98 (0.33 to
1.64)
Davidson et al.,
1990
40 53.6 US Mixed Conflict
Veterans
TCA Amitriptyline 8 71 SIP 0.07 (-0.55 to
0.70)
Davidson et al.,
1990
40 53.6 US Mixed Conflict
Veterans
TCA Amitriptyline 8 71 IES 0.41 (-0.22to
1.04)
Davidson et al.,
1990
33 53.6 US Mixed Conflict
Veterans
TCA Amitriptyline 8 71 CGI-S 0.81 (0.10 to
1.52)
Davidson et al.,
1990
33 53.6 US Mixed Conflict
Veterans
TCA Amitriptyline 8 71 SIP 0.26 (-0.43 to
0.94)
Davidson et al.,
1990
33 53.6 US Mixed Conflict
Veterans
TCA Amitriptyline 8 71 IES 0.53 (-0.16 to
1.23)
Davis et al., 2004 41 53.8 US Vietnam
Veterans
TCA Nefazodone 4 56 CAPS 0.90 (0.23 to
1.56)
Davis et al., 2004 41 53.8 US Vietnam
Veterans
TCA Nefazodone 8 56 CAPS 0.99 (0.32 to
1.66)
Davis et al., 2004 41 53.8 US Vietnam
Veterans
TCA Nefazodone 12 56 CAPS 0.29 (-0.35 to
0.93)
Davis et al., 2004 41 53.8 US Vietnam
Veterans
TCA Nefazodone 4 56 PCL-M 0.29 (-0.35 to
0.92)
Davis et al., 2004 41 53.8 US Vietnam
Veterans
TCA Nefazodone 8 56 PCL-M 0.26 (-0.38 to
0.90)
Davis et al., 2004 41 53.8 US Vietnam
Veterans
TCA Nefazodone 12 56 PCL-M 0.38 (-0.26 to
1.02)
Davis et al., 2008 82 55.2 US Mixed Conflict
Veterans
Anticonvulsant Divalproex 4 83 CAPS -0.05 (-0.48 to
0.38)
Davis et al., 2008 82 55.2 US Mixed Conflict
Veterans
Anticonvulsant Divalproex 8 83 CAPS -0.08 (-0.51 to
0.35)
Davis et al., 2008 82 55.2 US Mixed Conflict
Veterans
Anticonvulsant Divalproex 2 83 TOP-8 -0.04 (-0.47 to
0.39)
Davis et al., 2008 82 55.2 US Mixed Conflict
Veterans
Anticonvulsant Divalproex 4 83 TOP-8 -0.02 (-0.45 to
0.41)
Davis et al., 2008 82 55.2 US Mixed Conflict
Veterans
Anticonvulsant Divalproex 6 83 TOP-8 -0.04 (-0.47 to
0.39)
Davis et al., 2008 82 55.2 US Mixed Conflict
Veterans
Anticonvulsant Divalproex 8 83 TOP-8 0.02 (-0.41 to
0.45)
Davis et al., 2008 82 55.2 US Mixed Conflict
Veterans
Anticonvulsant Divalproex 2 83 CGI-S -0.10 (-0.54 to
0.33)
Davis et al., 2008 82 55.2 US Mixed Conflict
Veterans
Anticonvulsant Divalproex 4 83 CGI-S -0.31 (-0.75 to
0.12)
Davis et al., 2008 82 55.2 US Mixed Conflict
Veterans
Anticonvulsant Divalproex 6 83 CGI-S 0.00 (-0.43 to
0.43)
Davis et al., 2008 82 55.2 US Mixed Conflict
Veterans
Anticonvulsant Divalproex 8 83 CGI-S -0.21 (-0.64 to
0.23)
Frank et al., 1988 23 38 US Vietnam
Veterans
TCA Imipramine 8 NR IES 0.80 (-0.05 to
1.65)
Frank et al., 1988 22 38 US Vietnam
Veterans
MAOI Phenelzine 8 NR IES 1.68 (0.71 to
2.65)
(Continued)
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Table 2. (Continued)
Source Total
N
Age
(years)
Sample Drug Class Drug Name Duration
(weeks)
Adherence
(%)
PTSD
Scale
Hedges’ d
(95%CI)
Germain et al.,
2012
33 40.9 US Mixed Conflict
Veterans
Antihypertensive Prazosin 8 85 PCL-M 0.66 (-0.05 to
1.36)
Germain et al.,
2012
33 40.9 US Mixed Conflict
Veterans
Antihypertensive Prazosin 8 70 PCL-M 0.77 (0.06 to
1.47)
Hamner et al.,
2003
37 52 US Vietnam
Veterans
Antipsychotic Risperidone 5 NR CAPS -0.06 (-0.70 to
0.59)
Hertzberg et al.,
2000
12 46 US Vietnam
Veterans
SSRI Fluoxetine 12 92 DTS -0.27 (-1.40 to
0.87)
Hertzberg et al.,
2000
12 46 US Vietnam
Veterans
SSRI Fluoxetine 12 92 SIP 0.00 (-1.13 to
1.13)
Martenyi et al.,
2006
144 36.2 European Veterans SSRI Fluoxetine 12 97 TOP-8 0.95 (0.55 to
1.35)
Martenyi et al.,
2006
144 36.2 European Veterans SSRI Fluoxetine 12 97 CAPS 0.97 (0.57 to
1.37)
Martenyi et al.,
2006
144 36.2 European Veterans SSRI Fluoxetine 12 97 DTS 0.60 (0.21 to
1.00)
Martenyi et al.,
2006
144 36.2 European Veterans SSRI Fluoxetine 12 97 CGI-S 1.36 (0.95 to
1.78)
Martenyi et al.,
2006
144 36.2 European Veterans SSRI Fluoxetine 24 97 TOP-8 0.63 (0.12 to
1.13)
Martenyi et al.,
2006
144 36.2 European Veterans SSRI Fluoxetine 24 97 CAPS 0.42 (-0.09to
0.92)
Martenyi et al.,
2006
144 36.2 European Veterans SSRI Fluoxetine 24 97 DTS 0.31 (-0.19to
0.81)
Martenyi et al.,
2006
144 36.2 European Veterans SSRI Fluoxetine 24 97 CGI-S 1.63 (1.05 to
2.20)
Monnelly et al.,
2003
15 51.2 US Mixed Conflict
Veterans
Antipsychotic Risperidone 6 NR PCL-M 0.75 (-0.30 to
1.79)
Neylan et al.,
2006
54 44 US Mixed Conflict
Veterans
Antihypertensive Guanfacine 8 90 CAPS -0.08 (-0.61 to
0.45)
Neylan et al.,
2006
54 44 US Mixed Conflict
Veterans
Antihypertensive Guanfacine 8 90 IES -0.30 (-0.84 to
0.23)
Petrakis et al.,
2006
43 46.3 US Mixed Conflict
Veterans
ADI Disulfiram 12 NR CAPS 0.20 (-0.50 to
0.90)
Petrakis et al.,
2006
43 46.3 US Mixed Conflict
Veterans
Opioid
Antagonist
Naltrexone 12 NR CAPS -0.06 (-0.76 to
0.64)
Raskind et al.,
2003
10 53 US Vietnam
Veterans
Antihypertensive Prazosin 10 100 CAPS 1.29 (-0.07 to
2.65)
Raskind et al.,
2013
67 30.4 US Mixed Conflict
Veterans
Antihypertensive Prazosin 15 69 CAPS 0.48 (-0.01 to
0.97)
Reist et al., 1989 18 38.4 US Vietnam
Veterans
TCA Desipramine 4 67 IES 0.10 (-0.83 to
1.02)
Rothbaum et al.,
2008
77 42 US Mixed Conflict
Veterans
SNRI Venlafaxine 12 73 CAPS -0.11 (-0.84 to
0.62)
Zohar et al., 2002 42 39.5 Israeli Veterans SSRI Sertaline 10 NR CAPS 0.40 (-0.21 to
1.02)
Zohar et al., 2002 42 39.5 Israeli Veterans SSRI Sertaline 10 NR CGI-S 0.41 (-0.20 to
1.03)
Abbreviations: ADI, Aldehyde Dehydogenase Inhibitor; MAOI, Monoamine Oxidase Inhibitor; SNRI, Seratonin-Norepinephrine Reuptake Inhibitor; SSRI,
Selective Serotonin Reuptake Inhibitor; TCA, Tricyclic Antidepressant; NR, Not Reported; CAPS, Clinician Administered PTSD Scale; PCL-M, PTSD
Checklist-Military; TOP-8, Treatment Outcome PTSD Scale; CGI-S, Clinical Global Impression-Severity; SIP, Structured Interview for PTSD; IES, Impact
of Events Scale; DTS, Davidson Trauma Scale.
doi:10.1371/journal.pone.0126529.t002
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Moderator analysis. The overall multiple regression model for depression was significant-
ly related to effect size (QR(5) = 136.57; p< 0.001, R
2 = 0.85; QE(34) = 23.96, P = 0.900). The
pharmacotherapy x duration interaction (β = 0.06, z = 2.22, P = 0.026) was independently relat-
ed to effect size. The Johnson-Neyman procedure yielded a critical point for treatment duration
at 13.6 weeks (t = -2.03, p = 0.050) when comparing the effects of pharmacotherapy treatment
using SSRIs and Tricyclic antidepressants and other drug classes.
Fig 2. Forest Plot of the Unweighted Distribution of Pharmacotherapy Effects on PTSD.
doi:10.1371/journal.pone.0126529.g002
Pharmacotherapy for Combat PTSD
PLOSONE | DOI:10.1371/journal.pone.0126529 May 28, 2015 10 / 18
Secondary Moderator Analyses
The number of effects (k), mean effect size (Δ), 95% CI, p value, and I2 for each level of each
moderator for PTSD, anxiety, and depression models are presented in S3 Table, S4 Table and
S5 Table, respectively.
Fig 3. Forest Plot of the Unweighted Distribution of Pharmacotherapy Effects on Anxiety.
doi:10.1371/journal.pone.0126529.g003
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Differential Effects Analysis
A total of 28 effects concurrently measured PTSD, anxiety, and depressive symptom severity in
combat veterans with PTSD. These effects were derived from 6 studies (N = 365) which had an
average sample size of 61 (range = 18 to 144). Direct comparisons indicated no significant dif-
ference in the magnitude of the effect of pharmacotherapy on PTSD, anxiety, and depressive
Fig 4. Forest Plot of the Unweighted Distribution of Pharmacotherapy Effects on Depression.
doi:10.1371/journal.pone.0126529.g004
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symptom severity (QB(2) = 3.36, p = 0.186). These effects were further decomposed by type of
medication for descriptive purposes (S4 Fig).
Discussion
The cumulative evidence summarized in this review indicates that pharmacotherapy signifi-
cantly reduces PTSD, anxiety, and depressive symptom severity among combat veterans with
PTSD. The magnitude of the overall effects of pharmacotherapy on PTSD (Δ = 0.38), anxiety
(Δ = 0.42), and depressive symptoms (Δ = 0.52) were moderate and similar to effects seen in
previous reviews of pharmacotherapeutic effects on PTSD, anxiety, and depressive symptoms
in non-veteran group [12–14, 34–36]. The reduction in PTSD, anxiety, and depressive symp-
toms found among combat veterans using pharmacotherapy is equivalent to a number needed
to treat [37] of approximately 6 (4.0 to 8.8), 5 (3.8 to 7.0), and 4 (3.0 to 5.8), respectively. Differ-
ential analyses showed that pharmacotherapy does not elicit significantly different effects on
PTSD, anxiety, and depressive symptoms. These findings support the use of pharmacotherapy
as a concurrent treatment for PTSD, anxiety, and depression among combat veterans.
Heterogeneous main effects of pharmacotherapy for PTSD, anxiety, and depression re-
quired further examination of the specific treatment characteristics moderating the relation-
ship. The type of medication and the duration of the treatment were especially prominent
factors, and are discussed in greater detail in the following sections.
PTSD Symptom Severity
Reductions in PTSD symptom severity in response to pharmacotherapy among combat veter-
ans were greater for SSRI and Tricyclic antidepressants (Δ = 0.63) compared with other medi-
cations (Δ = 0.10) regardless of treatment duration. These findings support the involvement of
the serotonergic (5-HT) and noradrenergic (NE) systems in the etiology of PTSD [38]. For ex-
ample, evidence of the plausible role of the 5-HT system includes associated genetic variation
in a polymorphism of the 5-HT transporter and increased 5-HT neurotransmission in key
brain areas (e.g., hippocampus, amygdala) following traumatic events [38]. The present find-
ings also are consistent with previous evidence supporting the efficacy of both SSRI and tricy-
clic antidepressants in treating symptoms of PTSD despite some literature suggesting
resistance to these medication classes in combat-related PTSD [10, 39]. However, it is impor-
tant to examine these findings in the context of the IOM report which acknowledged the con-
cern that, although polypharmacy may result in improvement in PTSD symptoms, it may also
increase side effects and contribute to noncompliance to treatment [7]. Indeed, some evidence
has suggested that SSRI and Tricyclic antidepressant treatment may not be optimal for individ-
uals with anxiety symptoms [40], reiterating the call within the IOM report for further exami-
nation of pharmacotherapy for PTSD comorbid with other psychological symptoms and
disorders [7]. The following sections discuss the present findings for comorbid symptoms of
depression and anxiety within this context.
PTSD and Depressive Symptom Severity
Pharmacotherapy significantly improved comorbid depressive symptoms among combat vet-
erans with PTSD. Improvement in depressive symptom severity among combat veterans with
PTSD undergoing pharmacotherapy treatment varied according to an interaction between the
type of medication and duration of treatment. The effects of SSRI and Tricyclic antidepressants
on depressive symptoms were significantly greater than other medications up to a treatment
period of approximately 14 weeks, after which there was no longer significant difference be-
tween SSRI and Tricyclic antidepressants and other classes of medication. These findings
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support previous evidence suggesting that PTSD and depression are highly correlated, but in-
dependent, responses to trauma, plausibly resulting in differences in treatment response [40–
42]. Clinicians may benefit from addressing these differences throughout the course
of pharmacotherapy.
PTSD and depression occur frequently following traumatic exposure both concurrently and
as separate disorders [40, 42]. While PTSD and comorbid PTSD/depression are often indistin-
guishable, previous studies support the existence of depression as a separate construct in the
acute aftermath of trauma with its own unique characteristics and its own unique course of re-
covery [40]. PTSD symptoms are strongly predictive of later depression [40, 42]. For example,
non-cognitive factors such as hyperarousal have reliably preceded symptoms of depression
[42]. Cognitive factors such as intrusive memories also can begin to differentiate comorbid
PTSD/depression from depression alone as soon as three months post-trauma. These cognitive
factors may act as a mediator between PTSD and depression [40].
Our findings support the symptom-specific time course linking the bidirectional relation
between PTSD and depression. SSRIs and tricyclic antidepressants had a greater effect than
other drug classes in the management of PTSD symptoms regardless of treatment duration;
whereas, the differential therapeutic effects of these medications were most effective for depres-
sive symptoms until about three and a half months into treatment. In addition to alleviating
the core symptoms of PTSD, some SSRIs are also effective in treating common comorbidities,
such as depression and anxiety [43]. Thus, SSRIs can address depression symptoms directly
and also indirectly through non-cognitive factors (i.e., hyperarousal) which may facilitate pre-
vention of future depressive episodes [40, 42]. The slower onset of therapeutic effects found in
other drug classes, such as antipsychotics, may be associated with a mechanism of action relat-
ed to cognitive factors that can mediate the PTSD and depression relationship [42]. This medi-
ated response may be especially important for those patients that do not respond to short-term
treatment with SSRI or tricyclic antidepressants.
Although the IOM has questioned the merit of polypharmacy [7], monotherapy with tradi-
tional antidepressants may not be sufficient in patients with combat-related PTSD. For exam-
ple, atypical antipsychotics are an emerging class of drugs that may help alleviate PTSD
symptoms along cognitive symptom dimensions [12, 44]. Future studies should investigate
new combinations of pharmacotherapy that may provide improvement in both cognitive and
non-cognitive PTSD symptoms and aid the prevention of PTSD/depression comorbidity.
PTSD and Anxiety Symptom Severity
Pharmacotherapy significantly improved comorbid anxiety symptoms among combat veterans
with PTSD. Improvement in anxiety symptom severity among combat veterans with PTSD un-
dergoing pharmacotherapy treatment similarly varied according to an interaction between the
type of medication and duration of treatment. The effects of SSRI and Tricyclic antidepressants
on PTSD symptoms were significantly greater than other medications up to a treatment period
of approximately 5 weeks. However, following 11 weeks of treatment the effects of other medi-
cation classes were significantly greater than SSRIs and Tricyclic antidepressants.
Nearly 60% of veterans with PTSD report anxiety symptoms, and 20% have reported a
panic attack in the previous month [38]. The results reported here support other findings that
antidepressant medications, particularly SSRIs, have been effective in the treatment of not only
core symptoms of PTSD but also comorbid conditions including panic disorder, social anxiety
disorder, and generalized anxiety disorder [43]. These positive effects are likely related to neu-
ral circuits and substrates underlying acute and chronic stress responses and to trauma
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memory encoding and retrieval [9], and underscore the critical need to further examine effects
of pharmacotherapy on comorbid symptoms of anxiety among individuals with PTSD [7].
Comorbid PTSD/anxiety also is important to consider during PTSD treatment. For exam-
ple, higher depressive symptom severity was found among patients with PTSD and comorbid
panic disorder compared to patients without the comorbidity [45]. Thus, comorbid anxiety
may complicate not only treatment of PTSD, but also depression based-treatment, as it is relat-
ed to non-cognitive factors such as hyperarousal. Future studies should investigate how to
maximize the use of antidepressant agents in the treatment of not only PTSD and depression
following trauma, but also in the context of comorbid anxiety disorders.
Limitations
Limitations in the adequacy of reporting and the methodological rigor of included trials are of
note. Several trials did not provide adequate information about features of the intervention,
particularly regarding concomitant medication use and adherence/compliance to the pre-
scribed pharmacotherapy, while others did not utilize the most well-validated outcome mea-
sures available. Moreover, the limited number of effects derived from studies that examined
novel class treatments such as atypical antipsychotics or novel class antidepressants preclude
meaningful interpretations of findings for these drug classes and warrant future research. Fi-
nally, given both the prevalence of comorbid anxiety and depressive symptoms in PTSD and
the present findings which suggest that pharmacotherapy can concurrently attenuate these
symptoms among combat veterans with PTSD, future research should prioritize concurrent as-
sessment of related symptoms.
Conclusions
PTSD is a pervasive problem among combat veterans. Concurrent anxiety and depressive
symptoms are frequently reported among veterans with PTSD, and likely exacerbate the chron-
ic, debilitating effects of PTSD and the resistance to treatment. PTSD currently has few proven
pharmacotherapies. However, the evidence reviewed here suggests that pharmacotherapy has a
positive, but modest, therapeutic effect on PTSD, anxiety, and depressive symptom severity,
and it also successfully acts as a concurrent treatment for these symptoms among combat vet-
erans. This is especially evident for SSRI and Tricyclic antidepressants. The therapeutic effects
of SSRI and tricyclic antidepressant medications were greater for PTSD and occurred more
quickly for anxiety and depression than with other commonly prescribed medications. While
the pathophysiology of PTSD implicates many different neurotransmitter and neuroanatomi-
cal pathways, the delineation of the abnormalities in these chemical, structural, and neural sys-
tems will require time to fully understand. Until that time, the available evidence suggests that
SSRIs and Tricyclic antidepressants should be considered a first-line treatment while making
an allowance for other emerging classes of medication that may further alleviate symptoms in
refractory PTSD relative to cognitive dimensions such as avoidance and intrusive memories.
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